<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02185963</url>
  </required_header>
  <id_info>
    <org_study_id>SNUBH_ENDO05</org_study_id>
    <nct_id>NCT02185963</nct_id>
  </id_info>
  <brief_title>Effect of Rosuvastatin on Function of High Density Lipoprotein Cholesterol in Type 2 Diabetes</brief_title>
  <official_title>Effect of Rosuvastatin on Function of High Density Lipoprotein Cholesterol in Patients With Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Bundang Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Bundang Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The patients who have achieved LDL-C levels below the currently recommended targets may still
      experience cardiovascular events. To reduce further the risk of coronary heart disease (CHD),
      raising HDL-C and lowering TG may be the secondary therapeutic target. However, increased
      HDL-C levels do not mean increase in functional HDL-C. It also remains controversial whether
      functional HDL is more important than total circulating levels of HDL-C in reducing CHD.

      Actually, the increased concentration of HDL alone might be ineffective indicating that
      qualitative changes in HDL levels in response to drug interventions are required to result in
      clinical benefit.

      The investigators set up a clinical trial investigating effect of (rosuva)statin treatment on
      functional HDL-C levels particularly in Asian populations, who have relatively low HDL-C.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. Study design Study subject Number of Subjects (N = 30)

        2. Study outcome

           Primary outcome - functional HDL-C Secondary outcome - Non-HDL cholesterol

        3. Evaluation of functional aspect of HDL Cholesterol efflux from macrophages LDL-induced
           monocyte chemotactic activity (MCA) Assay Quantitation of gene expression of monocyte
           chemotactic protein-1 (MCP-1)
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2014</start_date>
  <completion_date type="Actual">May 2016</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Functional HDL-C</measure>
    <time_frame>12 weeks</time_frame>
    <description>Cholesterol efflux from macrophages
LDL-induced monocyte chemotactic activity (MCA) Assay
Quantitation of gene expression of monocyte chemotactic protein-1 (MCP-1)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Non-HDL-cholesterol = total cholesterol - HDL-C</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients with LDL-C &lt; 70 mg/dl and HDL &gt; 40 mg/dl in men; &gt; 50 in women</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Diabetes</condition>
  <arm_group>
    <arm_group_label>Rosuvastatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rosuvastatin will be started in type 2 DM and having 1 or more cardiovascular risk factors</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosuvastatin</intervention_name>
    <description>Rosuvastatin 20mg once a daily for 12 weeks</description>
    <arm_group_label>Rosuvastatin</arm_group_label>
    <other_name>Crestor</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Type 2 diabetes

          2. HbA1c ≥ 7.5%

          3. Age ≥ 30

          4. low HDL-C (&lt;40 mg/dl in men or &lt;50 mg/dl in women) and having 1 or more risk factors:
             1) Body mass index (BMI) ≥ 25 kg/m2 (overweight); 2) LDL-C level ≥ 130 mg/dl; 3) TG
             level ≥150 mg/dl; 4) Systolic blood pressure (SBP)/diastolic blood pressure (DBP)
             ≥140/90 mmHg or taking antihypertensive medication; 5) Current smoker; 6) Family
             history of CHD.

        Exclusion Criteria:

          1. Contraindication to rosuvastatin

          2. Pregnant or breast feeding women

          3. Reproductive-age women who refuse contraception

          4. Type 1 diabetes, gestational diabetes, or diabetes with secondary cause

          5. Chronic hepatitis B or C (except healthy carrier of HBV), liver disease (AST/ALT &gt;
             3-fold the upper limit of normal)

          6. Renal failure (Cr &gt; 2.0)

          7. Cancer within 5 years (except squamous cell cancer, cervical cancer, thyroid cancer
             with appropriate treatment)

          8. Not appropriate for lipid lowering treatment

          9. Medications which affect glycemic control

         10. Diseases which affect efficacy and safety of statin

         11. Other clinical trial within 30 days
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Soo Lim, PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Bundang Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>Seongnam</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 7, 2014</study_first_submitted>
  <study_first_submitted_qc>July 9, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 10, 2014</study_first_posted>
  <last_update_submitted>May 2, 2016</last_update_submitted>
  <last_update_submitted_qc>May 2, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 3, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Bundang Hospital</investigator_affiliation>
    <investigator_full_name>Soo Lim</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Diabetes</keyword>
  <keyword>Dyslipidemia</keyword>
  <keyword>HDL function</keyword>
  <keyword>Cholesterol efflux</keyword>
  <keyword>MCA assay</keyword>
  <keyword>MCP-1</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosuvastatin Calcium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

